Navigation Links
Enzyme-inhibition could revolutionize molecular imaging
Date:6/9/2014

St. Louis, Mo. (June 9, 2014) The prominent role a single enzyme plays in cancer imaging has eluded researchers for years, but not anymore. This discovery could pave new avenues in nuclear medicine. The enzyme, called neutral endopeptidase (NEP), has a way of breaking down most radiopeptide imaging agents in the body. Researchers have developed an elegant new concept that improves molecular imaging, according to study results presented during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

The sneaky enzyme has evaded studies with peptide tracers until now because it dwells not in tested blood serum but along the walls of blood vessels and other tissues. In order to combat the degradation of circulating radiopeptides, researchers co-injected a NEP inhibitor called phosphoramidon, derived from bacteria, at the same time as an agent for imaging with single photon emission computed tomography and computed tomography (SPECT/CT). They then applied this method of enzyme inhibition in multiple imaging studies involving a range of radionuclide and peptide counterparts. The results of this research showed consistent successup to 40 times the circulating radiopeptides when protected with phosphoramidon, compared to unprotected controls. This means the simple co-injection of an enzyme inhibitor promotes dramatically improved bioavailability and metabolic stability of radiopeptide imaging agents leading to higher uptake of the agent within targeted tumors and therefore better cancer imaging.

"Oncologists have long sought a powerful 'magic bullet' that can find tumors wherever they hide in the body so that they can be imaged and then destroyed," said Marion de Jong, PhD, a principal researcher for this study conducted at Erasmus Medical Center in Rotterdam, The Netherlands in cooperation with NCSR 'Demokritos' Athens, Greece. "Following this innovative approach, we have been able to induce, for the first time, an impressive improvement in the level of circulating and viable radiopeptides, leading to a spectacular increase in tumor uptake. Enzyme-inhibition in the body could translate into higher diagnostic sensitivity and improved therapeutic efficacy of radiopeptide drugs in cancer patients."

Not only were circulating radiopeptides increased in small animal models of varying tumor types, but the accumulation of radiopeptides also peaked at 14 times that of controls, which had not been treated with enzyme-inhibiting phosphoramidon. These results were clearly visualized by SPECT/CT imaging.


'/>"/>

Contact: Kimberly Brown
kbrown@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. A few circulating cancer cells could cue risk of metastases
2. Research could lead to new cancer assay, aid both dogs and humans
3. New definition of kidney disease for clinical trials could lead to new treatments
4. New amyloid-reducing compound could be a preventive measure against Alzheimers
5. Study explains how green tea could reduce pancreatic cancer risk
6. A cure for dry eye could be a blink away
7. Coating stents with vitamin C could reduce clotting risks
8. Could cannabis curb seizures? Experts weed through the evidence
9. Paper-based diagnostics, made with a scrapbooking tool, could curb hepatitis C pandemic
10. Pine bark substance could be potent melanoma drug
11. Biomarker test for Peripartum Cardiomyopathy could help reduce death after giving birth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and veteran ... the JFK Virgin Atlantic lounge. , Bensko is no stranger to the plight ... Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her riveting ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows , ... society in 11 countries across the Middle East and South Asia to embark on ... knowledge and ideas with the leading minds in their fields. , For the ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
Breaking Medicine Technology: